Aurora大麻报告有强劲的Q2 2026结果,销售额创纪录,利润率提高,无债务,提高了2026年的前景。 Aurora Cannabis reports strong Q2 2026 results with record sales, improved margins, and no debt, raising its 2026 outlook.

Aurora大麻在2026年财政上取得了强劲的Q2结果,净收入为9 040万美元,逐年增加11%,其驱动因素是全球医疗大麻销售额创下纪录,达到7 050万美元,增幅为15%。 Aurora Cannabis posted strong fiscal Q2 2026 results with $90.4 million in net revenue, up 11% year over year, driven by record global medical cannabis sales of $70.5 million, a 15% increase. 澳大利亚、德国、波兰和英国的国际需求上升,而经调整的《欧洲双边投资条约》的需求量猛增52%至1 540万开曼元,经调整的净收入翻了一番以上。 International demand rose in Australia, Germany, Poland, and the U.K., while adjusted EBITDA surged 52% to C$15.4 million and adjusted net income more than doubled. 在季度结束时,该公司的现金为1.419亿科多巴元,大麻生意没有债务,提高了2026年的前景,突出显示了利润率的提高和现金自由流通的正数。 The company ended the quarter with C$141.9 million in cash and no debt in its cannabis business, raised its outlook for 2026, and highlighted improved margins and positive free cash flow. Trulieve 报告称，2025 年第三季度收入为 2.88 亿美元，其中自由现金流为 6400 万美元，调整后息税折旧摊销前利润率为 36%，77% 的交易由其奖励计划推动。 Trulieve reported $288 million in revenue for Q3 2025, with $64 million in free cash flow, 36% adjusted EBITDA margin, and 77% of transactions driven by its rewards program. 该公司扩大了业务,推出了新产品,并计划赎回3.68亿美元的票据。 The company expanded operations, launched new products, and plans to redeem $368 million in notes. orgigram的首席执行官批评加拿大2025年预算缺乏对合法大麻工业的支持,并警告说没有政策改革,竞争力就会丧失。 Organigram’s CEO criticized Canada’s 2025 budget for lacking support for the legal cannabis industry, warning of lost competitiveness without policy reforms.